Addressing unmet medical needs with small-molecule drugs targeting mRNA
First written in FY2023. 1 of 3 entries say "Reframed", first in FY2025. Latest entry: 2026-05-11.
No other company in this theme has enough history to compare yet.
- 2026-05-11AdvancedBusiness Alliances
「The purpose is to create state-of-the-art, world-leading small-molecule drugs targeting mRNA.」
The direction of creating mRNA-targeting small-molecule drugs advanced into a specific joint exploratory research project with SpiroChem. - FY2025ReframedAnnual report
「Our management philosophy is to realize and develop a warm, hopeful society in which patients with any disease do not have to give up because no treatment is available or lament that they cannot receive the optimal treatment. We pursue this through a platform business for mRNA-targeted small-molecule drug discovery, in which our proprietary platform technology is provided to multiple pharmaceutical companies through joint drug-discovery research and other activities, as well as through a pipeline business in which we discover drugs in-house.」
While maintaining the philosophy of contributing to unmet medical needs, the wording has broadened from small-molecule drug discovery alone to encompass the discovery of all mRNA-targeted drugs through the in-house pipeline business. - FY2023First statedAnnual report
「We are working to discover small-molecule drugs that target messenger RNA (mRNA), thereby contributing to the realization of a warm, hopeful society in which patients with any disease do not have to give up because no treatment is available or lament that they cannot receive the optimal treatment.」
The company has adopted a policy of fulfilling its social mission by addressing unmet medical needs through mRNA-targeted small-molecule drug discovery.